source
- Novartis’ BTK inhibitor remibrutinib cuts MS relapse rates in Phase 3, setting up FDA filingNovartis reported that its BTK inhibitor remibrutinib, already approved for chronic spontaneous urticaria, lowered annualized relapse rates in two Phase 3 studies of relapsing multiple sclerosis wh…
- Funding announcements can hint at upcoming biotech hiring opportunitiesFunding announcements serve as early signals that a biotech company may soon expand its workforce, giving job seekers a chance to reach out before roles are formally posted. Alex Benjamin, vice pr…